Payer PolicyActive
Purified Cortrophin Gel® (repository corticotropin injection)
EVICORE-MEDICAL_DRUG-3DC792E5
EviCore by Evernorth
Effective: February 1, 2024
Updated: January 13, 2026
created · Dec 4, 2025
Policy Summary
Purified Cortrophin Gel (repository corticotropin) is generally not approved/covered despite FDA‑approved indications because of insufficient updated clinical efficacy evidence and potential long‑term safety concerns. Requests would only be considered for an FDA‑approved indication and must meet the plan’s coverage guidelines, though this policy provides no specific documentation requirements or detailed criteria.
Coverage Criteria Preview
Key requirements from the full policy
"Rheumatic disorders"
Sign up to see full coverage criteria, indications, and limitations.